Hutchmed (china) Share Discussion Threads

[nerdofsteel] 29/9/2019 17:03

Press Release - Sunday 29th September

hxxps://www.chi-med.com/news/news-archive/?cat=13,11,14,21&in=7

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy
and Safety Data Presented at the 2019 ESMO Annual Meeting
– Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients
with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study –
– Preparations underway for the potential submission of surufatinib New Drug Application (“NDA”) by
year end 2019 for non-pancreatic NET tumors in China –
– Treatment options are limited for the 90% of all global NET patients whose tumors originate outside
of the pancreas. Surufatinib represents an important potential advancement for these patients –
– Conference call and webcast to be held on Monday, September 30, 2 p.m. Barcelona time to review
surufatinib data –

[nerdofsteel] 29/9/2019 07:57

U.S. Treasury Says No Plans to Block Chinese Listings ‘at This Time’



Treasury official says option is not on the table at this time
Trump advisers are divided on path forward and possible action

[nerdofsteel] 28/9/2019 18:00

For the record, HCM is listed as an HK ADR not a China ADR which may make a
difference, I hope

[nerdofsteel] 28/9/2019 17:57

Thankyou so much for posting s/jack, it just so happens I bought ADR's during the mayhem on Friday afternoon without realising why all China related ADR's were tumbling

I wonder how the President will simply de-list Alibaba at nearly $500bn!?

[nerdofsteel] 28/9/2019 11:12

I agree, this development must surely prompt the Company to push ahead with their HK IPO. There are plenty of other Biotechs pressing head their at the moment so I cannot see a reason why not.

[shaker44] 27/9/2019 18:53

Maybe this is the kick they need to get.on with the HK listing. More about marketability than intrinsic value

[steeplejack] 27/9/2019 18:16

From Bloomberg.This is why the stock's tumbling."Among the options the Trump administration is considering ,delisting Chinese companies from US stock exchanges and limiting Americans' exposure to the Chinese market through government pension funds .Exact mechanisms for how to do so have not yet been worked out and any plan is subject to approval by President Trump,who has given the green light to the discussion according to one person close to the deliberations".

[mad foetus] 27/9/2019 09:08

And as an ex-holder I can't get past the quoted 8% spread when considering buying in. Feels like the advisors here have not helped the company at all

[nerdofsteel] 27/9/2019 08:59

The most disappointing aspect is the Company is no longer valued based on normal metrics, DCF models and normal ways that the Company was valued on previously. Instead, its value is being diminished by the botched secondary.

I would like the Company to provide an update on the HK IPO. As it stands currently they have not said it is shelved and there are plenty of other HK Biotech IPO's taking place. I assume they are waiting for the botched secondary, the overhang and the 90- day lockup to clear, the latter of which has just completed.

[steeplejack] 26/9/2019 21:07

Down again in the US.Closing around 3 quid equivalent.

This is what I thought might occur when MS screwed up the placing.They would get left with a stick and the price would be overhung and start to drift..However,the subsequent share holding disclosures suggested that the placing equity had ultimately gone into relatively safe institutional hands and the price looked to be heading back to around $24 placing mark. However,it all got rather confused and I wouldn’t be surprised if some stock did indeed get left with MS and that’s what is exacerbating the current down trend.Anyway,the fall in the price this week is not that out of sync with other US biotechs,in particular gene therapy stocks.They have been slammed.Loss-making biotechs are not in vogue as investors run for big cap safe havens.....and those safe havens ....do they include tobacco stocks like Imperial Brands!

[nerdofsteel] 26/9/2019 08:44

The 90 day lockup period has just ended this week

It's also interesting to note that staff and senior Managers were given various Share Options in the last year at prices way above today's level, so I suspect they are very surprised we currently sit at March 2017 levels given the huge progress.

Historically the Company has seen years of share price stagnation followed by very rapid price rises (2010, 2014, 2015, 2016 for example)

[lauders] 26/9/2019 02:40

I personally wouldn't mind if HCM stays at these levels for a few more weeks. I might, if some decent news materializes at some of my other investments, have some cash I can use to top-up if they remain at around 300p. I think we are just going through a bad phase at present and HCM will rebound sometime before Xmas.

[cisk] 25/9/2019 19:15

Like NoS, I'm a long term holder, first buying in 2007.

Bumps in the road are to be expected for a pharma, and I agree that the recent price weakness has little to do with the fundamentals of the company, but more with the HK political situation, and the botched fund raising.

We now have what we've never had before, a free float big enough for HCM to be taken over, or at least for someone to acquire a significant stake in the company. I've long felt that the valuation has been held back because of such a small free float.

Given biotech valuations in the US, I feel HCM seems remarkably cheap given their pipeline potential, and the other parts of the business that make money...

[nerdofsteel] 25/9/2019 17:58

As a Holder and accumulator for 10 years I am comfortable to continue to Buy, the valuation of the Company goes through long periods of stagnation, followed by periods of over-extension and under-extension.

I believe in the Company, its brilliant Management, its strategy and its execution. Most recent setbacks are due to circumstances beyond its control.

Given the fact that staff and senior leadership have extensive share options and large tranches of personal stock, I am sure the entire staff at all levels are as keen as we are to see it successful and increase in value.

This will be circa $15-20bn by 2030 IMO

[shaker44] 25/9/2019 17:01

You may be right or there may be a fund raise in the offing. Difficult to keep them totally quiet from all potential sellers - and shorters.
Like you I feel fully loaded, but also scarred by the very poorly executed Hutchison stake reduction. I won't be buying just yet

[dbadvn] 25/9/2019 16:24

I'm assuming this is related to both Market conditions and the last traunch that Hutchison group or Morgan Stanley have to get rid of on their behalf to get below 50% holding.

My expectation is that, market conditions aside this will turn around rapidly in Q4/Q1. Wish I could buy more here but already have filled my boots....

[shaker44] 25/9/2019 12:03

I feel like doing the same but I don't understand why it fell so far so fast. Too often I have averaged down on shares I really believed in, but caught a falling knife.

[nerdofsteel] 25/9/2019 10:41

I have added substantially today, this is currently at levels last seen 2.5 years ago

[steeplejack] 24/9/2019 16:46

Less said the better I suppose.

Added-US looking to close around £3 equivalent.Biotechs very weak on Wall Street so HCM is not alone but is clearly very unloved.

[nerdofsteel] 19/9/2019 10:58

I was in HK last year on the day Fruquintinib was approved, the share price dropped - not what I expected. Let's hope we don't get the same with Surufatinib.

The 90 day lockup for the Secondary expires early next week, as someone kindly pointed out on LSE. Let's hope some institutional Investors get involved or start to build larger positions once CKH/HHHL make clear their intentions and we possibly get a further update re; the HK listing. A number of Biotechs have continued with their listings now Carrie Lam has ditched the extradition Bill and things seem to have calmed down a little.

[sportii] 18/9/2019 03:39

I remain optimistic. It’s indeed depressing to see last two years ‘dull’ performance of the sp, a drop of more than 30% from the peaks of £5.90 (£59 prior to share split) in December 2017. What the company urgently needs is, at least, one drug candidate out of the many in the pipeline to ‘click’. Any one, either among the autoimmune therapy side or cancer therapy side. Hope it’s going to happen soon.

[lauders] 18/9/2019 02:34

I remain convinced this will be a $15-20bn mcap Company within the next 10 years if the pipeline is mainly successful.

Think many would agree BUT the highlighted part of your statement is the key NofS and we, nor anyone else, knows how that WILL play out. We can only hope it all comes good. More highs and lows to come here for certain.

[thornyone] 17/9/2019 16:09

nhb, it happened at the beginning of the day. Short selling indicator.
Exploiting what they are convinced is a weak company. Might as well go along for the ride :-)

[nhb001] 17/9/2019 14:22

The latest swoon was very sudden and happened mid way through the US trading day yesterday. Does anyone know what news caused it?